Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: A randomized controlled trial

Clinical Infectious Diseases

Volumn 51, Issue 9, 2010, Pages 1081-1089

  Mulenga, V ^a   Cook, A ^b   Walker, A S ^b   Kabamba, D ^a   Chijoka, C ^a   Ferrier, A ^b   Kalengo, C ^a   Kityo, C ^c   Kankasa, C ^a   Burger, D ^d   Thomason, M ^b   Chintu, C ^a   Gibb, Diana M ^b  

^a UNIVERSITY TEACHING HOSPITAL   (Zambia)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; LAMIVIR S BABY; LAMIVIR S JUNIOR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE; STAVUDINE; TRIOMUNE BABY; TRIOMUNE JUNIOR; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CD4+ T LYMPHOCYTE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FORMULATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; ZAMBIA;

ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; CHILD; DRUG-INDUCED LIVER INJURY; EXANTHEMA; HIV INFECTIONS; HUMANS; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZAMBIA;

EID: 77958591432     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656628     Document Type: Article

References (27)

1. World Health Organization (WHO). Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: a progress report. Geneva, Switzerland: WHO, 2009. http://www.who.int/hiv/pub/2009progressreport/en/index. html. Accessed 18 October 2009.
2. Havens PL, Gibb DM. Increasing antiretroviral drug access for children with HIV infection. Pediatrics 2007; 119(4):838-845.
3. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8(8):477-489.
4. Chokephaibulkit K, Plipat N, Cressey TR, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS 2005; 19(14):1495-1499.
5. Ellis JC, L'Homme RF, Ewings FM, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12(2):253-260.
6. L'Homme R, Kabamba D, Ewings FM, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22(5):557-565.
7. Baylor M, Ayime O, Truffa M, Denson A, Johann-Liang R. Hepatotoxicity associated with nevirapine use in children. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. 2005. Abstract 776.
8. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996; 174(4):713-721.
9. Barlow-Mosha L, Musoke P, Ajuna P, et al. Early effectiveness of Triomune in HIV infected Ugandan children. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment. 2005. Abstract WeOa0103.
10. World Health Organization (WHO). Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access - recommendations for a public health approach (2006 revision). Geneva, Switzerland: WHO, 2006.
11. Mulenga V, Fillekes Q, Kabamba D, et al. Pharmacokinetics of nevirapine in 3- to 6-kg, HIV-infected infants taking pediatric fixed-dose combination tablets. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. 2009. Abstract 881.
12. Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 1994; 13(22):2359-2367.
13. D'Aquila RT, Hughes MD, Johnson VA, et al; National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124(12):1019-1030.
14. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA 1998; 279(12):930-937. (Pubitemid 28136082)
15. Menson EN, Walker AS, Sharland M, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 2006; 332(7551):1183-1187.
16. Dart Trial Team. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 2008; 13(1):6-16.
17. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375(9709):123-131.
18. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32(1):124-129.
19. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19(5):463-471. (Pubitemid 40515849)
20. Kesselring AM, Wit FW, Sabin CA, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009; 23(13):1689-1699.
21. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. AIDS 2003; 17(11):1639-1647.
22. Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC pediatr 2007; 7:13.
23. Nyandiko WM, Ayaya S, Nabakwe E, et al. Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. J Acquir Immune Defic Syndr 2006; 43(4):418-425.
24. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007; 298(16):1888-1899.
25. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002; 359(9308):733-740.
26. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002; 2(2):93-102. (Pubitemid 36114143)
27. Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis 2009; 49(12):1915-1927.